Vir Biotechnology rises after naming Theravance's Sawaf as CFO
01/10/2026 17:46
BUZZ-Vir Biotechnology rises after naming Theravance's Sawaf as CFO ** Vir Biotechnology's VIR.O shares rise more than 3% to $11.53 in afternoon trading
** Co appoints Aziz Sawaf as Chief Financial Officer effective Oct. 5
** Aziz joins from Theravance Biopharma, where he was CFO from 2023
** He is succeeding former CFO Jason O'Byrne, who left VIR on Aug. 3, to pursue another opportunity
** All 10 analysts covering VIR are bullish and their median PT is $20, according to data compiled by LSEG
** Including session moves, stock up 91% YTD
(Reporting by Miraanta Lowrance in Bengaluru)
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO